Диссертация (1140276), страница 25
Текст из файла (страница 25)
– P. 1067-1073.151.Gardner, D.G. Greenspan’s Basic and Clinical Endocrinology / D.G. Gardner,D. Shoback. – 9th ed. – [S.l.]:McGraw-Hill, 2011. – 912 p.152.Ginsberg, M.D. Neuroprotection for ischemic stroke: past, present and future /M.D. Ginsberg // Neuropharmacology. – 2008. – Vol.55, №3. – P. 363-389.153.Guo, H. Vascular endothelial growth factor: an attractive target in the treatmentof hypoxic/ischemic brain injury / H.
Guo, H. Zhou, J. Lu [et al.] // NeuralRegeneration Research. – 2016. – Vol. 11, №1. – P. 174-179.154.Guzik, A. Stroke Epidemiology and Risk Factor Management / A. Guzik, C.Bushnell // Continuum (Minneap Minn). – 2017. – Vol.23,№1, CerebrovascularDisease. – P. 15-39.150155.Hacke, W. Intravenous Thrombolysis With Recombinant Tissue PlasminogenActivator for Acute Hemispheric Stroke The European Cooperative Acute Stroke Study(ECASS) / W. Hacke, M. Kaste, C. Fieschi [et al.] // JAMA. – 1995.
– Vol.274, №13. –P. 1017-1025.156.Hacke, W. Randomised double– blind placebo– controlled trial of thrombolytictherapy with intravenous alteplase in acute ischemic stroke (ECASS II) / W. Hacke, M.Kaste, C. Fieschi [et al.] // Lancet. – 1998. – Vol.352. – P. 1245-1251.157.Hacke, W. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS). A PhaseII MRI – Based 9– Hour Window Acute Stroke Thrombolysis Trial With IntravenousDesmoteplase / W. Hacke, G. Albers, Y. Al-Rawi [et al.] // Stroke. – 2005.
– Vol.36. –P. 66-73.158.Hacke, W. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemicstroke / W. Hacke, M. Kaste, E. Bluhmki [et al.] // N Engl J Med. – 2008. – Vol.359,№13. – P. 1317-1329.159.Hamblin, M.R. Photobiomodulation for traumatic brain injury and stroke /M.R. Hamblin // J Neurosci Res. – 2018. – Vol.96, №4. – P. 731-743.160.Hao, Z.
A cohort study of pa ents with anemia on admission and fatality a eracute ischemic stroke / Z. Hao, B. Wu, D. Wang [et al.] // J Clin Neurosci. –2013. –Vol.20. – P. 37-42.161.Hata, R.Evolution of brain infarction after transient focal cerebral ischemia inmice/ R.Hata, K.Maeda, D.Hermann [et al.] // J Cerebr Blood Flow Metab. – 2000. –Vol.20, №6. – P. 937-946.162.Hegstad, E. Amino-acid release from human cerebral cortex during simulatedischaemia in vitro / E. Hegstad, J. Berg-Johnsen, T.S.
Haugstad [et al.]// ActaNeurochir (Wien). – 1996. – Vol.138, №2. – P. 234-241.163.Heiss, W.D. Cerebrolysin in patients with acute ischemic stroke in Asia: resultsof a double-blind, placebo-controlled randomized trial / W.D. Heiss, M. Brainin, N.M.Bornstein [et al.] // Stroke. – 2012. – Vol. 43. – P. 630-636.164.Heiss, W.D.The ischemic penumbra: how does tissue injury evolve? /W.D.Heiss // Ann N Y Acad Sci. – 2012. – Vol.1268. – P. 26-34.151165.Heit, J.J.Perfusion Computed Tomography for the Evaluation of AcuteIschemic Stroke: Strengths and Pitfalls / J.J.Heit, M.
Wintermark // Stroke. – 2016. –Vol.47, №4. – P. 1153-1158.166.Henderson, T.A.Near-infrared photonic energy penetration – can infraredphototherapy effectively reach the human brain? / T.A. Henderson, L.D. Morries//Neuropsychiatr Dis Treat. – 2015. – Vol.11. – P.
2191-2208.167.Hermann, D.M. Implications of vascular endothelial growth factor forpostischemic neurovascular remodeling / D.M. Hermann, A. Zechariah// J.Cereb. Blood Flow Metab. – 2009. – Vol.29. – P. 1620-1643.168.Hong, Z. A double-blind, placebo-controlled, randomized trial to evaluate thesafety and efficacy of Cerebrolysin in patients with acute ischemic stroke in AsiaCASTA / Z. Hong, H. Moessler, N. Bornstein [et al.] // Int J Stroke. – 2009. – Vol.4,№5. – P. 406-412.169.Hossmann, K.A.
Periinfarct depolarizations / K.A. Hossmann // Cerebrovasc.Brain Metab. Rev. – 1996. – Vol.8. – P. 195-208.170.Hossmann, KA. Experimental models for the investigation of brain ischemia /KA. Hossmann // Cardiovasc Res. – 1998. – Vol.39. – P.106-120.171.Hossmann, K.A.The two pathophysiologies of focal brain ischemia:implications for translational stroke research / K.A. Hossmann // J Cereb Blood FlowMetab. – 2012.
– Vol.32, №7. – P. 1310-1316.172.Huang, Y. Ischemic Stroke. “Acidotoxicity” Is a Perpetrator / Y. Huang, J.O.McNamara // Cell. – 2004. – Vol. 118, №6. – P. 665-666.173.Huang, Y.Y. Biphasic dose response in low level light therapy / Y.Y. Huang,A.C. Chen, J.D. Carroll [et al.] // Dose Response. – 2009. – Vol. 7, №4. – P.
358-383.174.Huisa, B.N.Incremental treatments with laser therapy augments goodbehavioral outcome in the rabbit small clot embolic stroke model / B.N. Huisa, Y. Chen,B.C. Meyer [et al.] // Lasers Med Sci. – 2013. – Vol.28, №4. – P. 1085-1089.175.Jauch, E.C. Guidelines for the early management of patients with acuteischemic stroke: a guideline for healthcare professionals from the American Heart152Association/American Stroke Association / E.C. Jauch, J.L.
Saver, H.P. Jr Adams [etal.] // Stroke. – 2013. – Vol.44, №3. – P. 870-947.176.Jean LeBlanc, N. Vascular Endothelial Growth Factor Isoform-B StimulatesNeurovascular Repair After Ischemic Stroke by Promoting the Function of Pericytes viaVascular Endothelial Growth Factor Receptor-1 / N. Jean LeBlanc, R. Guruswamy, A.ElAli [et al.] // Mol Neurobiol. – 2018. – Vol.55, №5. – P. 3611-3626.177.Jenkins, L.W. The role of postischemic recirculation in the development ofischemic neuronal injury following complete cerebral ischemia / L.W. Jenkins, J.T.Povlishock, W.
Lewelt [et al.] // Acta Neuropathol (Berl). – 1981. – Vol.55. – P. 205220.178.Jin, R. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells/ R. Jin, G. Yang, G. Li.// J Leukoc Biol. – 2010. –Vol.87, №5. – P. 779-789.179.Jittiwat, J. Laser Acupuncture at GV20 Improves Brain Damage and OxidativeStress in Animal Model of Focal Ischemic Stroke / J. Jittiwat // J Acupunct MeridianStud. – 2017. – Vol.10, №5. – P. 324-330.180.Kaiafa, G.Anemia and stroke: Where do we stand? / G. Kaiafa, C.Savopoulos, I.
Kanellos [et al.] // Acta Neurol Scand. – 2017. – Vol.135, №6. – P. 596602.181.Karu, T.I. Cellular effects of low power laser therapy can be mediated by nitricoxide / T.I. Karu, L.V. Pyatibrat, N.I. Afanasyeva // Lasers Surg Med. – 2005. – Vol.36,№4. – P. 307-314.182.Karu, T. Is it time to consider photobiomodulation as a drug equivalent? / T.Karu // Photomed Laser Surg. – 2013.
– Vol.31, №5. – P. 189-191.183.Ke, Q.Hypoxia-inducible factor-1 (HIF-1) / Q. Ke, M. Costa // MolPharmacol. – 2006. – Vol.70, №5. – P. 1469-1480.184.Khan, M. Promoting endothelial function by S-nitrosoglutathione through theHIF-1α/VEGF pathway stimulates neurorepair and functional recovery followingexperimental stroke in rats / M. Khan, T.S. Dhammu, F.
Matsuda [et al.] // Drug DesDevel Ther. – 2015. –Vol.9. – P. 2233-2247.153185.Kiessling, M.Focal cerebral ischemia: molecular mechanisms and newtherapeutic strategies / M.Kiessling, K.A. Hossmann // Brain Pathol. – 1994. – Vol.4,№1. – P. 21-22.186.Komnig, D. Faim2 contributes to neuroprotection by erythropoietin in transientbrain ischemia / D. Komnig, K.
Gertz, P. Habib // J Neurochem. – 2018. –Vol.145, №3.– P. 258-270.187.Kumral, A.Erythropoietin downregulates bax and DP5 proapoptotic geneexpression in neonatal hypoxic-ischemic brain injury / A. Kumral, S. Genc, E. Ozer [etal.] // Biol Neonate. – 2006.
– Vol.89, №3. – P. 205-210.188.Ladurner, G. Neuroprotective treatment with cerebrolysin in patients with acutestroke: a randomized controlled trial / G. Ladurner, P. Kalvach, H. Moessler [et al.] // JNeural Transm. – 2005. – Vol.112. – P.
415-428.189.Lampl, Y. Infrared laser therapy for ischemic stroke: a new treatment strategy:results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1) / Y. Lampl, J.A.Zivin, M. Fisher [et al.] // Stroke. – 2007. – Vol. 38, №6. – P. 1843-1849.190.Lands, W.E.M. Oxygen requirement for prostaglandin biosynthesis / W.E.M.Lands, J. Sauter, G.W. Stone // Prostaglandins Med.
– 1978. – №2. – P. 117-120.191.Lapchak, P.A. Taking a light approach to treating acute ischemic strokepatients: transcranial near-infrared laser therapy translational science / P.A. Lapchak //Ann Med. – 2010. – Vol.42, №8. – P. 576-586.192.Lapchak, P.A. Fast neuroprotection (fast-NPRX) for acute ischemic strokevictims: the time for treatment is now / P.A. Lapchak // Transl Stroke Res. – 2013. –Vol.4, №6. – P. 704-709.193.Lapchak, P.A. Transcranial Near-Infrared Laser Transmission (NILT) Profiles(800 nm): Systematic Comparison in Four Common Research Species / P.A.Lapchak,P.D.Boitano, P.V.
Butte [etal.] // PLoSOne.– 2015. – Vol.10, №6. – P. e0127580.194.Lapchak, P.A.Transcranial Near-Infrared Laser Therapy for Stroke: How toRecover from Futility in the NEST-3 Clinical Trial / P.A. Lapchak, P.D.Boitano // ActaNeurochir Suppl. – 2016. – Vol.121. – P. 7-12.154195.Lee, M. Efficacy of Intra– Arterial Fibrinolysis for Acute Ischemic StrokeMeta-Analysis of Randomized Controlled Trials / M. Lee, K.-S. Hong, J.L.
Saver //Stroke. – 2010. – Vol.41. – P. 932-937.196.Lees, K.R. NXY-059 for acute ischemic stroke / K.R. Lees, J.A. Zivin, T.Ashwood [et al.] // N. Engl. J. Med. – 2006. – Vol.354. – P. 588-600.197.Lewandowski, C.A. Combined Intravenous and Intra-Arterial r-TPA VersusIntra-Arterial Therapy of Acute Ischemic Stroke. Emergency Management of Stroke(EMS) Bridging Trial / C.A.
Lewandowski, M. Frankel, T.A. Tomsick [et al.] // Stroke.– 1999. – Vol.30, №12. – P. 2598-2605.198.Li, C. Post-stroke Constraint-induced Movement Therapy Increases FunctionalRecovery, Angiogenesis, and Neurogenesis with Enhanced Expression of HIF-1αandVEGF / C. Li, B. Zhang, Y. Zhu [et al.] // Curr Neurovasc Res. – 2017. – Vol.14, №4.– P. 368-377.199.Liebeskind, D.S. Computed Tomography Perfusion in Acute Ischemic Stroke:Is It Ready for Prime Time? / D.S.Liebeskind, M.W.Parsons, M.Wintermark [et al.] //Stroke. – 2015. – Vol.46, №8. – P. 2364-2367.200.Lindsberg, P.J.Therapy of basilar artery occlusion: a systematic analysiscomparing intra-arterial and intravenous thrombolysis / P.J.Lindsberg, H.P. Mattle //Stroke.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
